About Concordia International Corp. (NASDAQ:CXRX)
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:CXRX
- CUSIP: N/A
- Web: www.concordiarx.com
- Market Cap: $58.3 million
- Outstanding Shares: 51,143,000
- 50 Day Moving Avg: $1.33
- 200 Day Moving Avg: $1.49
- 52 Week Range: $1.06 - $5.55
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.42
- P/E Growth: 0.000
- Annual Revenue: $677.25 million
- Price / Sales: 0.08
- Book Value: ($27.60) per share
- Price / Book: -0.04
- EBITDA: $326.58 million
- Net Margins: -269.97%
- Return on Equity: -83.96%
- Return on Assets: -0.62%
- Debt-to-Equity Ratio: -2.48%
- Current Ratio: 1.89%
- Quick Ratio: 1.62%
- Average Volume: 360,916 shs.
- Beta: 0.64
- Short Ratio: 8.57
Frequently Asked Questions for Concordia International Corp. (NASDAQ:CXRX)
What is Concordia International Corp.'s stock symbol?
Concordia International Corp. trades on the NASDAQ under the ticker symbol "CXRX."
How were Concordia International Corp.'s earnings last quarter?
Concordia International Corp. (NASDAQ:CXRX) issued its quarterly earnings data on Friday, August, 11th. The company reported $0.19 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.15 by $0.04. The business earned $160.80 million during the quarter, compared to analysts' expectations of $160.92 million. Concordia International Corp. had a negative net margin of 269.97% and a negative return on equity of 83.96%. The company's revenue was down 30.6% on a year-over-year basis. During the same period last year, the company posted $1.38 EPS. View Concordia International Corp.'s Earnings History.
When will Concordia International Corp. make its next earnings announcement?
Where is Concordia International Corp.'s stock going? Where will Concordia International Corp.'s stock price be in 2017?
5 brokerages have issued 1-year price targets for Concordia International Corp.'s shares. Their predictions range from $0.50 to $13.50. On average, they anticipate Concordia International Corp.'s stock price to reach $8.00 in the next year. View Analyst Ratings for Concordia International Corp..
Who are some of Concordia International Corp.'s key competitors?
Some companies that are related to Concordia International Corp. include Aralez Pharmaceuticals (ARLZ), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Evoke Pharma (EVOK), SCYNEXIS (SCYX), Juniper Pharmaceuticals (JNP), Histogenics Corporation (HSGX), Amryt Pharma PLC (AMYT), Intellipharmaceutics International (IPCI), Pernix Therapeutics Holdings (PTX), Cellectar Biosciences (CLRB), Apricus Biosciences (APRI), Immune Pharmaceuticals (IMNP), Venture Life Group PLC (VLG), Eyegate Pharmaceuticals (EYEG), Neuralstem (CUR), Galena Biopharma (GALE) and Aegerion Pharmaceuticals (AEGR).
Who are Concordia International Corp.'s key executives?
Concordia International Corp.'s management team includes the folowing people:
- Wayne Kreppner, President, Chief Operating Officer
- Allan Oberman, Chief Executive Officer, Director
- David J. Price, Chief Financial Officer
- Graeme Duncan, President - Company's International Segment
- Arijit Mookerjee, Managing Director, Chief Financial Officer - Operations
- Adeel Ahmad, Chief Financial Officer of AMCo
- Francesco Tallarico, Chief Legal Officer and Secretary
- Jordan M. Kupinsky J.D., Non-Executive Independent Chairman of the Board
- Douglas N. Deeth, Independent Director
- Rochelle Fuhrmann, Independent Director
How do I buy Concordia International Corp. stock?
Shares of Concordia International Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concordia International Corp.'s stock price today?
MarketBeat Community Rating for Concordia International Corp. (NASDAQ CXRX)MarketBeat's community ratings are surveys of what our community members think about Concordia International Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Concordia International Corp. stock can currently be purchased for approximately $1.07.
Consensus Ratings for Concordia International Corp. (NASDAQ:CXRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||5 Sell Ratings|
|Consensus Rating:||Sell (Score: 1.00)|
|Consensus Price Target: ||$8.00 (651.17% upside)|Consensus Price Target History for Concordia International Corp. (NASDAQ:CXRX)
Analysts' Ratings History for Concordia International Corp. (NASDAQ:CXRX)
(Data available from 10/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/14/2017||Canaccord Genuity||Reiterated Rating||Sell||High|
|2/8/2017||TD Securities||Downgrade||Hold -> Reduce||N/A|
|12/9/2016||Scotiabank||Downgrade||Sector Perform -> Underperform||$2.00 -> $0.50||N/A|
|12/7/2016||Royal Bank Of Canada||Downgrade||Sector Perform -> Underperform||N/A|
|11/7/2016||Bloom Burton||Downgrade||Hold -> Sell||N/A|
|9/27/2016||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Neutral||N/A|
|8/15/2016||CIBC||Downgrade||Sector Perform -> Underperform||$7.80||N/A|
|8/15/2016||GMP Securities||Downgrade||Buy -> Hold||N/A|
|3/31/2016||Laurentian||Reiterated Rating||Buy||$60.00 -> $55.00||N/A|
|3/28/2016||Laurentian Bank of Canada||Lower Price Target||Buy||$60.00 -> $55.00||N/A|
|3/21/2016||Dundee Securities||Lower Price Target||$46.50 -> $45.00||N/A|
Earnings History for Concordia International Corp. (NASDAQ:CXRX)Earnings History by Quarter for Concordia International Corp. (NASDAQ CXRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2017|| || || || || || || || |
|8/11/2017||6/30/2017||$0.15||$0.19||$160.92 million||$160.80 million||View||N/A|
|5/10/2017||3/31/2017||$0.52||($0.37)||$168.09 million||$160.56 million||View||N/A|
|3/15/2017||12/31/2016||$0.55||$0.13||$181.65 million||$170.40 million||View||N/A|
|11/7/2016||Q316||$1.03||($0.33)||$206.00 million||$185.50 million||View||Listen|
|8/12/2016||Q216||$1.38||$1.38||$229.76 million||$231.70 million||View||N/A|
|5/13/2016||Q116||$1.54||$1.35||$231.00 million||$228.50 million||View||N/A|
|3/23/2016||Q415||$1.32||$1.24||$166.60 million||$191.90 million||View||N/A|
|11/12/2015||Q315||$1.43||$1.46||$93.11 million||$94.90 million||View||N/A|
|8/13/2015||Q215||$1.02||$0.96||$78.60 million||$77.51 million||View||N/A|
Earnings Estimates for Concordia International Corp. (NASDAQ:CXRX)
Current Year EPS Consensus Estimate: $0.49 EPS
Next Year EPS Consensus Estimate: $-0.75 EPS
Dividend History by Quarter for Concordia International Corp. (NASDAQ CXRX)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Concordia International Corp. (NASDAQ:CXRX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Concordia International Corp. (NASDAQ:CXRX)
Latest Headlines for Concordia International Corp. (NASDAQ:CXRX)
Concordia International Corp. (CXRX) Chart for Tuesday, October, 17, 2017